Bilateral Refractive Lens Exchange with a Hydrophobic Trifocal Intraocular Lens Authors: Camille Bosc, Eloïse Le Malefan, Pauline Boury, Mélanie Bernier Published: 2026 ABSTRACT PurposeTo evaluate the visual and refractive outcomes in patients who underwent bilateral refractive lens exchange (RLE) with the trifocal hydrophobic FineVision HP IOL.MethodsThis prospective, single-center, non-comparative study enrolled 70 eyes of 35 patients implanted bilaterally with the FineVision HP IOL (Beaver-Visitec International, Inc. USA). Postoperative outcomes at 3 months included manifest refraction, monocular and binocular logMAR uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), distance-corrected intermediate visual acuity (DCIVA, at 60 cm), and distance-corrected near visual acuity (DCNVA, at 40 cm). The binocular defocus curve was also registered.Results94.29% of eyes showed a spherical equivalent within ±0.50D and all within ±1.00D. 95.71% of eyes showed a refractive cylinder of ≤0.50D and all ≤1.00D. The mean spherical equivalent and refractive cylinder were 0.16 ± 0.27D and −0.18 ± 0.21D, respectively. Mean binocular CDVA, DCIVA and DCNVA were −0.12 ± 0.06, 0.15 ± 0.07 and 0.03 ± 0.05 logMAR, respectively. 88.57% and 100% of patients achieved a cumulative binocular CDVA of ≥20/16 and ≥20/20, respectively. Furthermore, 51.43% and 91.43% patients achieved a cumulative binocular DCIVA of ≥20/25 and ≥20/32, respectively; and 71.43% and 100% of patients achieved a cumulative binocular DCNVA of ≥20/20 and ≥20/25, respectively. The safety and efficacy indexes were 1.07 and 1.01, respectively. The defocus curve showed a peak of maximum visual acuity, better than 20/16, at distance, with a continuous smooth reduction in visual acuity for intermediate distances, followed by a secondary peak close to 20/20 at near.ConclusionsThe FineVision HP IOL demonstrated favorable short-term refractive accuracy and visual performance in this prospective cohort, although larger comparative studies with longer follow-up are warranted. Introduction The use of crystalline lens surgery as a refractive modality in patients without cataracts, known as refractive lens exchange (RLE), has increased in popularity among cataract and refractive surgeons.1 The limitations of corneal refractive surgery and the advanced age of patients have led to the expanding use of this modality. Furthermore, the implantation of presbyopia correcting intraocular lenses (IOLs) after crystalline lens removal offers an alternative for the correction of presbyopia eliminating the future need for cataract surgery.2 The use of RLE with multifocal IOLs has been found as a safe, effective and predicable refractive surgery modality in presbyopic patients from the early 2000s.3,4 Different publications using multifocal lenses have positioned this technique as an important modality in the refractive armamentarium,3 although it is not suitable for every patient seeking refractive surgery.4 Specifically, RLE with multifocal IOLs provides considerable benefits especially, particularly in high hyperopes, presbyopes, and patients with borderline or soon to be clinically significant cataracts who request refractive surgery.5 However, it has been emphasized that this procedure should be performed with caution in emmetropes and patients with low refractive errors due to the potential incidence of intolerable halos and the need for secondary procedures.6 Technical advances in presbyopia correcting IOLs during the last 20 years has expanded the clinical indications of these lenses, leading to the development of bifocal, trifocal and extended depth of focus models.7 For patients considering a multifocal IOL due to presbyopia, bilateral implantation of a trifocal IOL might be an optimal option to achieve spectacle independence.8 Indeed, trifocal models demonstrate superior visual acuity and spectacle independence at near distances when compared to standard monofocal, bifocal, extended depth of focus and enhanced monofocals post-cataract surgery.9 One widely used trifocal IOL is the hydrophobic FineVision HP IOL, which has demonstrated good refractive outcomes and excellent visual performance.10 Previous versions of the FineVision lens, made of hydrophilic material and with different haptics designs, have shown favourable outcomes in RLE procedures.11–18 However, to the best of our knowledge, no studies focusing exclusively on RLE patients implanted with this hydrophobic model have been conducted. Thus, the main purpose of this prospective clinical study was to evaluate the visual and refractive outcomes in patients who underwent bilateral RLE with the trifocal hydrophobic FineVision HP IOL. Methods Patients and Surgical Procedure This was a prospective clinical study that collected data from patients in the Institut Ophtalmologique de l’Ouest (IOO) Jules Verne (Nantes, France) submitted to bilateral RLE surgery involving FineVision HP IOL implantation. Patients provided written consent for their surgical intervention, data was anonymised, and no additional intervention beyond standard care was performed. Either toric or non-toric models of this lens were used depending on the pre-existing corneal astigmatism. The study was approved by the IOO Review Board (IOO-2026-RLE-1) and conducted in accordance with Good Clinical Practices and the principles of the Declaration of Helsinki with patients signing the informed consent form. Inclusion criteria considered patients with age between 40 and 70 years, candidates for RLE followed by implantation of the trifocal FineVision HP IOL and able to attend the follow-up examinations up to the last postoperative visit. Exclusion criteria considered patients with glaucoma, retinal detachment, ocular inflammation, macular degeneration, retinopathy, and neuro-ophthalmic or corneal diseases. RLE surgery was performed by a single surgeon (CB) by means of standard phacoemulsification using the EVA NEXUS device (DORC Dutch Ophthalmic Research Centre (International) B.V., Zuidland, The Netherlands). The procedure for all interventions was the use of the pop- and pre-chop technique, a capsulorrhexis (about 5.0 mm of diameter), and the FineVision HP IOL inserted into the capsular bag. Diffractive Trifocal Intraocular Lens The FineVision HP (POD F GF) is a single-piece diffractive trifocal IOL of glistening-free (GF) hydrophobic acrylic material that provides 2 additions (one for +3.50D and the other for +1.75D, both at the IOL plane). The haptics platform (POD) has a double C-loop design; and the available powers range from +10.00D to +35.00D (0.50D-steps) and cylindrical powers at the IOL plane of 1/1.50/2.25/3/3.75/4.50/5.25 or 6D. The total diameter is 10.75 mm and the optic diameter is 6.15 mm. Pre- and Post-Operative Examinations The preoperative examination included a standard ophthalmological examination with slit lamp and dilated fundoscopy, corrected distance visual acuity (CDVA), manifest refraction, and optical biometry using the IOLMaster 700 biometer (Carl Zeiss Meditec, Jena, Germany). The Barrett and Barrett toric formulas were used to calculate the specific IOL power, and all eyes were targeted for emmetropia. Postoperative outcomes were recorded at the 3-month follow-up and consisted of: a slit lamp examination, subjective manifest refraction (sphere, cylinder and axis), monocular and binocular logMAR uncorrected distance visual acuity (UDVA), CDVA, distance corrected intermediate visual acuity (DCIVA) at 60 cm, and distance-corrected near visual acuity (DCNVA) at 40 cm. A double-angle plot analysis19 was carried out for the vector analysis. The binocular defocus curve was measured from +1.00D to −4.00D in 0.5D steps. Regarding the RLE procedure, safety and efficacy indexes were also calculated. Statistical Analysis Data from the different examinations were entered into a Microsoft Excel spreadsheet (2019, v. 16.43, Microsoft Corporation, Redmont, WA, USA). The mean, standard deviation, and ranges were calculated for continuous variables (age, visual acuity, refraction, biometric parameters and IOL powers), while counts and percentages were used for categorical variables (sex and cumulative visual acuity). Standard graphs for reporting refractive and visual acuity outcomes in IOL-based refractive surgery were plotted.20 Results A total of 70 eyes of 35 patients (20 males) with a mean age of 57.66 ± 4.93 years (range from 50 to 67) were included in this study. All patients completed the 3-month follow-up. Table 1 shows the demographic and preoperative characteristics of the analyzed cohort. Of the total, 46 eyes received a spherical IOL model and 24 eyes a toric IOL model.Table 1Demographics and Preoperative Characteristics of Patients Included in This Study, Shown as Means, Standard Deviations, and RangesFineVision HPEyes (n)70Patients (n)35Sex (male/female)20/15Age (y)57.66 ± 4.93 (50 to 67)Sphere (D)1.47 ± 1.54 (−3.25 to 5.75)Cylinder (D)−0.44 ± 0.39 (−1.75 to 0.00)Spherical Equivalent (D)1.25 ± 1.51 (−3.25 to 5.00)Monocular CDVA (logMAR)−0.01 ± 0.04 (−0.10 to 0.00)Intraocular Pressure (mmHg)16.41 ± 3.15 (8.90 to 24)Axial length (mm)23.32 ± 0.74 (21.51 to 25.18)K1 (D)42.99 ± 1.33 (40.19 to 45.60)K2 (D)43.63 ± 1.38 (40.84 to 46.80)ACD (mm)3.08 ± 0.30 (2.58 to 3.74)LT (mm)4.58 ± 0.28 (3.91 to 5.20)WTW (mm)12.03 ± 0.28 (11.50 to 12.70)IOL spherical power (D)22.83 ± 2.45 (17.00 to 29.00)IOL cylindrical power (D)1.17 ± 0.24 (1.00 to 1.50)Abbreviations: IOL, intraocular lens; D, dioptres. Table 1Demographics and Preoperative Characteristics of Patients Included in This Study, Shown as Means, Standard Deviations, and RangesFineVision HPEyes (n)70Patients (n)35Sex (male/female)20/15Age (y)57.66 ± 4.93 (50 to 67)Sphere (D)1.47 ± 1.54 (−3.25 to 5.75)Cylinder (D)−0.44 ± 0.39 (−1.75 to 0.00)Spherical Equivalent (D)1.25 ± 1.51 (−3.25 to 5.00)Monocular CDVA (logMAR)−0.01 ± 0.04 (−0.10 to 0.00)Intraocular Pressure (mmHg)16.41 ± 3.15 (8.90 to 24)Axial length (mm)23.32 ± 0.74 (21.51 to 25.18)K1 (D)42.99 ± 1.33 (40.19 to 45.60)K2 (D)43.63 ± 1.38 (40.84 to 46.80)ACD (mm)3.08 ± 0.30 (2.58 to 3.74)LT (mm)4.58 ± 0.28 (3.91 to 5.20)WTW (mm)12.03 ± 0.28 (11.50 to 12.70)IOL spherical power (D)22.83 ± 2.45 (17.00 to 29.00)IOL cylindrical power (D)1.17 ± 0.24 (1.00 to 1.50)Abbreviations: IOL, intraocular lens; D, dioptres. Demographics and Preoperative Characteristics of Patients Included in This Study, Shown as Means, Standard Deviations, and Ranges Abbreviations: IOL, intraocular lens; D, dioptres. Refractive Accuracy Figure 1 shows the refractive outcomes at 3 months postoperatively, with Figure 1A representing the spherical equivalent and Figure 1B the refractive cylinder. At this follow-up, 94.29% of eyes were within ±0.50D and 100% were within ±1.00D. The mean spherical equivalent obtained was 0.16 ± 0.27D (ranging from −0.38D to 1.00D), the mean spherical refraction was 0.25 ± 0.27D (ranging from −0.25D to 1.00D), and the mean refractive cylinder was −0.18 ± 0.21D (ranging from 0.00D to −0.75D). Regarding the postoperative refractive cylinder distribution (Figure 1B), 95.71% of eyes were ≤0.50D, 100% were ≤1.00D, and, specifically, 82.86% showed a value ≤0.25D. Figure 2 displays the double-angle plots of corneal astigmatism before the surgery and refractive astigmatism at 3 months postsurgery, showing a higher concentration of data points after the intervention (less astigmatism). Specifically, the postoperative refractive astigmatism centroid was 0.02 ± 0.28D at 52 degrees, and the mean absolute value dropped from 0.64 ± 0.40D preoperatively to 0.18 ± 0.21D postoperatively. Figure 1Distribution of postoperative spherical equivalent refraction (A) and refractive cylinder (B) at 3 months postoperatively.Image A: Bar chart with Y-axis showing percent of eyes (0 to 50 percent) and X-axis showing Postoperative Spherical Equivalent Refraction (diopter). Categories: less than negative 2.00; negative 2.00 to negative 1.51; negative 1.50 to negative 1.01; negative 1.00 to negative 0.51; negative 0.50 to negative 0.14 (8.57 percent); negative 0.13 to positive 0.13 (45.71 percent); positive 0.14 to positive 0.50 (40.00 percent); positive 0.51 to positive 1.00 (5.71 percent); positive 1.01 to positive 1.50; positive 1.51 to positive 2.00; greater than positive 2.00. Top right text: plus or minus 0.50 diopter: 94.29 percent; plus or minus 1.00 diopter: 100 percent. Image B: Bar chart with Y-axis showing percent of eyes (0 to 90 percent) and X-axis showing Postoperative Refractive Cylinder (diopter). Categories: less than or equal to 0.25 (82.86 percent); 0.50 (12.86 percent); 0.75 (4.29 percent); 1.00. Top right text: less than or equal to 0.50 diopter: 95.71 percent; less than or equal to 1.00 diopter: 100 percent.A pair of bar charts showing postoperative spherical equivalent refraction and postoperative refractive cylinder. Figure 2Double-angle plots of preoperative corneal astigmatism (A) and postoperative refractive astigmatism (B) at 3 months postoperatively. Centroids, mean absolute values, and standard deviations are also shown.Image A shows a polar scatter plot of preoperative corneal astigmatism with angle markings from 0 to 180 degrees and concentric rings indicating magnitude, each representing 1.00 diopter. Data points cluster near the center, with a centroid marker and a 95% confidence ellipse. The centroid is 0.31 diopter at 85 degrees plus or minus 0.70 diopter and the mean absolute is 0.64 diopter plus or minus 0.40 diopter. Image B displays a similar plot for postoperative refractive astigmatism, with data points more tightly clustered. The centroid is 0.02 diopter at 52 degrees plus or minus 0.28 diopter and the mean absolute is 0.18 diopter plus or minus 0.21 diopter. Both images have the same angle markings and ring spacing, with N = 70.Two polar scatter plots comparing corneal and refractive astigmatism, with tighter clustering in B. Distribution of postoperative spherical equivalent refraction (A) and refractive cylinder (B) at 3 months postoperatively. Double-angle plots of preoperative corneal astigmatism (A) and postoperative refractive astigmatism (B) at 3 months postoperatively. Centroids, mean absolute values, and standard deviations are also shown. Visual Acuity at Different Distances and Defocus Curve Table 2 shows the average, standard deviation, and ranges for distance, intermediate, and near visual acuity outcomes under monocular and binocular conditions. Mean binocular values were −0.12 ± 0.06, 0.15 ± 0.07 and 0.03 ± 0.05 logMAR for CDVA, DCIVA and DCNVA, respectively. The safety and efficacy indexes were 1.07 and 1.01, respectively. Figure 3A plots the cumulative percentage of eyes with a given monocular UDVA, CDVA, DCIVA, and DCNVA, whereas Figure 3B displays the cumulative percentage of patients with a given binocular UDVA, CDVA, DCIVA and DCNVA. For distance vision, 38.57% and 97.14% of the eyes had a cumulative monocular CDVA of ≥20/16 and ≥20/20, respectively (Figure 3A); these percentages increased to 88.57% and 100% under binocular conditions, respectively (Figure 3B). For intermediate vision, cumulative monocular DCIVA was ≥20/25 in 34.29% of eyes and ≥20/32 in 71.43% of eyes (Figure 3A), increasing to 51.43% and 91.43% under binocular conditions, respectively (Figure 3B). For near vision, cumulative monocular DCNVA was ≥20/20 in 22.86% of eyes and ≥20/35 in 97.14% of eyes (Figure 3A), improving to 71.43% and 100% under binocular conditions, respectively (Figure 3B). The binocular photopic defocus curve at 3 months postoperatively is illustrated in Figure 4 (mean ± standard deviation). It shows a peak of best visual acuity better than 20/16 (−0.11 ± 0.06 logMAR) at distance (0D of vergence), with a smooth, continuous reduction in visual acuity at intermediate distances, followed by a secondary peak close to 20/20 (0.01 ± 0.08 and 0.02 ± 0.09 logMAR) at near (−2.50 and −3.00D of vergence, respectively). Figure 3Cumulative percentages of eyes (A) monocular and patients (B) binocular at 3 months postoperatively with a given postoperative uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), distance-corrected intermediate visual acuity (DCIVA) at 60 cm, and distance-corrected near visual acuity (DCNVA) at 40 cm.Image A and B display grouped bar charts with legends UDVA, CDVA, DCIVA, DCNVA. Both have x-axis labeled ′Cumulative Visual Acuity (20/x or better)′ with categories: 20/16, 20/20, 20/25, 20/32, 20/40. The y-axis for Image A is ′Cumulative percent of Eyes′ and for Image B is ′Cumulative percent of Patients′, both ranging 0-100%. Image A values: - 20/16: UDVA 30, CDVA 38.57 - 20/20: UDVA 78.57, CDVA 97.14, DCIVA 2.86, DCNVA 22.86 - 20/25: UDVA 95.71, CDVA 100, DCIVA 34.29, DCNVA 97.14 - 20/32: UDVA 100, CDVA 100, DCIVA 71.43, DCNVA 97.14 - 20/40: UDVA 100, CDVA 100, DCIVA 97.14, DCNVA 100 Image B values: - 20/16: UDVA 82.86, CDVA 88.57, DCNVA 2.86 - 20/20: UDVA 100, CDVA 100, DCIVA 5.71, DCNVA 71.43 - 20/25: UDVA 100, CDVA 100, DCIVA 51.43, DCNVA 100 - 20/32: UDVA 100, CDVA 100, DCIVA 91.43, DCNVA 100 - 20/40: UDVA 100, CDVA 100, DCIVA 100, DCNVA 100.Two grouped bar charts showing cumulative visual acuity outcomes for monocular eyes and binocular patients. Figure 4Mean binocular distance-corrected visual acuity (logMAR) as a function of chart vergence from +1.0 D to −4.0D (defocus) at 3 months after FineVision HP intraocular lens (IOL) implantation. Error bars represent standard deviations. The right y-axis shows Snellen acuity in feet. Distance (cm) is shown in the upper x-axis for intermediate distances. The curve has been smoothed for graphical representation.A line graph showing binocular visual acuity as a function of vergence.Table 2Refractive and Visual Acuity (logMAR) Outcomes at Distance, Intermediate and Near Vision Shown as Means, Standard Deviations, and RangesFineVision HPSpherical Equivalent (D)0.16 ± 0.27 (−0.38 to 1.00)Sphere (D)0.25 ± 0.27 (−0.25 to 1.00)Refractive Cylinder (D)−0.18 ± 0.21 (0.00 to −0.75)Monocular UDVA−0.01 ± 0.08 (−0.20 to 0.20)Binocular UDVA−0.11 ± 0.06 (−0.20 to 0.20)Monocular CDVA−0.04 ± 0.06 (−0.20 to 0.10)Binocular CDVA−0.12 ± 0.06 (−0.20 to 0.10)Monocular DCIVA0.19 ± 0.09 (0.00 to 0.40)Binocular DCIVA0.15 ± 0.07 (0.00 to 0.30)Monocular DCNVA0.08 ± 0.06 (0.00 to 0.30)Binocular DCNVA0.03 ± 0.05 (−0.10 to 0.10)Abbreviations: D, dioptres; UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; DCIVA, distance corrected intermediate visual acuity; DCNVA, distance corrected visual acuity. Cumulative percentages of eyes (A) monocular and patients (B) binocular at 3 months postoperatively with a given postoperative uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), distance-corrected intermediate visual acuity (DCIVA) at 60 cm, and distance-corrected near visual acuity (DCNVA) at 40 cm. Mean binocular distance-corrected visual acuity (logMAR) as a function of chart vergence from +1.0 D to −4.0D (defocus) at 3 months after FineVision HP intraocular lens (IOL) implantation. Error bars represent standard deviations. The right y-axis shows Snellen acuity in feet. Distance (cm) is shown in the upper x-axis for intermediate distances. The curve has been smoothed for graphical representation. Table 2Refractive and Visual Acuity (logMAR) Outcomes at Distance, Intermediate and Near Vision Shown as Means, Standard Deviations, and RangesFineVision HPSpherical Equivalent (D)0.16 ± 0.27 (−0.38 to 1.00)Sphere (D)0.25 ± 0.27 (−0.25 to 1.00)Refractive Cylinder (D)−0.18 ± 0.21 (0.00 to −0.75)Monocular UDVA−0.01 ± 0.08 (−0.20 to 0.20)Binocular UDVA−0.11 ± 0.06 (−0.20 to 0.20)Monocular CDVA−0.04 ± 0.06 (−0.20 to 0.10)Binocular CDVA−0.12 ± 0.06 (−0.20 to 0.10)Monocular DCIVA0.19 ± 0.09 (0.00 to 0.40)Binocular DCIVA0.15 ± 0.07 (0.00 to 0.30)Monocular DCNVA0.08 ± 0.06 (0.00 to 0.30)Binocular DCNVA0.03 ± 0.05 (−0.10 to 0.10)Abbreviations: D, dioptres; UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; DCIVA, distance corrected intermediate visual acuity; DCNVA, distance corrected visual acuity. Refractive and Visual Acuity (logMAR) Outcomes at Distance, Intermediate and Near Vision Shown as Means, Standard Deviations, and Ranges Abbreviations: D, dioptres; UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; DCIVA, distance corrected intermediate visual acuity; DCNVA, distance corrected visual acuity. Discussion It has been reported that presbyopic patients seeking spectacle independence constitute an important indication for RLE, taking into account that multifocal IOLs continue to evolve, proving their efficacy while maintaining an adequate risk-benefit ratio.1 This procedure is now a well-stabilised tool in the cataract and refractive surgeon’s armamentarium. In the current study, we show our outcomes following bilateral FineVision HP IOL implantation after RLE surgery. Overall, 65.71% of eyes received the spherical IOL model and 34.29% the toric IOL model. Our results reveal that RLE with the FineVision HP IOL can successfully restore near and intermediate visual acuity in patients with presbyopia. To date, no previous publications have evaluated this specific IOL model in RLE procedures; however, other models of this lens have been used in this type of surgery. Table 3 shows a summary of these prior studies, indicating the sample, study design, IOL model (material and haptics), follow-up period, and any specific conditions such as the use of capsular tension rings, eyes previously submitted to corneal laser vision correction, or the use of mix-and-match strategy. In general, the available literature supports the use of the FineVision lenses in RLE surgery.Table 3Peer-Reviewed Publications Using the FineVision Trifocal Intraocular Lens in Refractive Lens Exchange SurgeryAuthorsYearSample(Eyes)Type of StudyIntraocularLens ModelFollow-Up(Months)IndicationNistad et al112017388ProspectiveMicro F3Use of CTRPOD FTLevinger et al12201926ProspectiveMicro F6UnilateralBrenner et al132019241RetrospectiveMicro F6After CLVCPOD FFernández-García et al142021169RetrospectiveMicro FAt least 3Unilateral vs bilateral emmetropic eyesDjodeyre et al152021266RetrospectiveMicro F8.83 ± 5.69*Hyperopic < 40 years2668.89 ± 6.45*Hyperopic > 50 yearsBrenner et al16202335,206RetrospectiveMicro F3BilateralPOD FTFernández-García et al172023690RetrospectiveMicro FAt least 3Unilateral vs bilateral emmetropic eyesMayordomo-Cerdá et al18202530RetrospectiveMicro FAt least 3Mix-and-matchPOD FCurrent study202670ProspectiveFineVision HP3BilateralNotes: * mean.Abbreviations: CTR, capsular tension ring; CLVS, corneal laser vision correction. Table 3Peer-Reviewed Publications Using the FineVision Trifocal Intraocular Lens in Refractive Lens Exchange SurgeryAuthorsYearSample(Eyes)Type of StudyIntraocularLens ModelFollow-Up(Months)IndicationNistad et al112017388ProspectiveMicro F3Use of CTRPOD FTLevinger et al12201926ProspectiveMicro F6UnilateralBrenner et al132019241RetrospectiveMicro F6After CLVCPOD FFernández-García et al142021169RetrospectiveMicro FAt least 3Unilateral vs bilateral emmetropic eyesDjodeyre et al152021266RetrospectiveMicro F8.83 ± 5.69*Hyperopic < 40 years2668.89 ± 6.45*Hyperopic > 50 yearsBrenner et al16202335,206RetrospectiveMicro F3BilateralPOD FTFernández-García et al172023690RetrospectiveMicro FAt least 3Unilateral vs bilateral emmetropic eyesMayordomo-Cerdá et al18202530RetrospectiveMicro FAt least 3Mix-and-matchPOD FCurrent study202670ProspectiveFineVision HP3BilateralNotes: * mean.Abbreviations: CTR, capsular tension ring; CLVS, corneal laser vision correction. Peer-Reviewed Publications Using the FineVision Trifocal Intraocular Lens in Refractive Lens Exchange Surgery Notes: * mean. Abbreviations: CTR, capsular tension ring; CLVS, corneal laser vision correction. The outcomes obtained in our sample show the good accuracy of the procedure: 94.29% of eyes were within ±0.50D and all within ±1.00D of spherical equivalent, while 95.71% of eyes showed ≤0.50D of postoperative cylinder. Furthermore, the mean values for both the spherical equivalent (0.16 ± 0.27D) and refractive cylinder (−0.18 ± 0.21D) were below a quarter of diopter. Note that the accuracy of this procedure using a trifocal lens is extremely important and requires, in addition to careful patient selection, precise preoperative biometric measurements and accurate IOL power calculation. In our study, all calculations were based on the Barrett and Barrett toric formulas. Previous studies using other FineVision IOL model showed also good predictability (see Table 3). The first study reporting RLE data with a FineVision IOL model was published by Nistad et al11 in 388 eyes to determine whether the use of a capsular tension ring increased refractive stability in two FineVision IOL models. They found that up to 7% of eyes had a hyperopic shift of greater than +0.75D and the use of a capsular tension ring had no statistically significant effect in eyes implanted with the Micro F IOL, and it appeared to reduce refractive stability, although not significantly, in those with the POD FT IOL. Brenner et al13 assessed 241 eyes with previous myopic or hyperopic corneal laser vision correction at 6 months postoperatively, obtaining 80.9% within ±0.50D and 97.9% within ±1.00D of emmetropia. Fernández-García et al14,17 analyzed the outcomes between unilateral and bilateral surgery in emmetropic patients with presbyopia across two retrospective studies of 169 and 690 eyes. In the study with the largest sample, a total of 93.3% of eyes were within the 0.50D range in postoperative manifest refractive spherical equivalent. Djodeyre et al15 retrospectively analyzed two groups of 266 eyes each, one under 40 years old and another over 50 years old, with at least 3 months of follow-up. They found that 92% of eyes were within ±0.50D and 100% of eyes were within ±1.00D in the younger sample. These values were similar to the older control group: 93% and 100%, respectively (P > 0.05). The formulas used in their cohort were Haigis, Hoffer Q, and Holladay 2. They concluded that this procedure is predictable, which aligns with our findings as demonstrated by our accuracy (see Figure 1). To date, the study with the largest sample size was carried out by Brenner et al,16 involving 35,206 eyes implanted with the Micro F and POD FT IOL models. At 3 months postoperatively, they reported a mean manifest refractive spherical equivalent of 0.00 ± 0.40D with about 86% of the eyes (n = 30,124) within ±0.50D. These authors detailed that from 2013 to 2015, they used the SRK/T formula with optimised constants, and from 2016 onward, they used the Haigis formula with a triple constant optimisation. In this regard, they indicated that refining IOL power calculation improved accuracy and reduced the enhancement rate from 20% in 2013 to 12% in 2019. The accuracy of the outcomes reported in our study was similar, showing the predictability of the procedure (our mean spherical equivalent value was 0.16 ± 0.27D using other formulas). Brenner et al16 indicated that refractive enhancements should be considered as part of the treatment and should be explained to the patient before surgery. As discussed, modern formulas could provide better outcomes by reducing the standard deviation of mean spherical equivalent values, which inherently reduces the number of touch up procedures using an excimer laser. Overall, our findings using the HP IOL model indicate that this procedure is highly predictable. Achieving emmetropia is critical to maximize the performance of trifocal IOLs across all distances. Table 2 shows the mean visual acuity values at different distances, while Figure 3 shows the cumulative percentage of eyes or patients (under monocular or binocular conditions) for a given value of visual acuity. For distance vision, mean binocular values were better than 20/26, better than 20/32 and about 20/20 for CDVA, DCIVA and DCNVA respectively (see Table 2). The cumulative visual acuity outcomes further confirmed the good performance of the lens, with all patients achieving a CDVA of ≥20/20, 91.43% a DCIVA of ≥20/32, and 71.43% a DCNVA of ≥20/20 (Figure 3). This aligns with the defocus curve profile obtained, which showed two peaks of best visual acuity: one at distance (better than 20/16) and another at near (about 20/20; see Figure 4). Our results are somewhat better than those reported by Brenner et al13 in their sample. Note that their cohort considered patients who had previously undergone corneal laser vision correction. They obtained, binocularly, that 85% of patients had simultaneous UDVA and UNVA of 0.9 or better (Snellen) and Jaeger 3, respectively. They reported a mean safety index of 0.98 ± 0.09 (range 0.80 to 1.29) and a mean efficacy index of 0.81 ± 0.18 (range 0.30 to 1.22), showing that IOL power calculation remains a challenge in lens-based refractive surgery, especially in this specific group of patients. Our results were similar to those reported by other authors implanting this lens in virgin eyes. For example, Fernández-García et al14 found a safety index of 1 in unilateral and bilateral emmetropic eyes, and an efficacy index of 0.98 in the unilateral group and 0.99 in the bilateral group. In their second study,17 they found efficacy and safety indexes of 0.98 and 1.01, respectively, for the whole cohort. Their mean binocular UDVA, CDVA, UIVA (80 cm) and UNVA (40 cm) were −0.01 ± 0.03, −0.02 ± 0.03, 0.21 ± 0.13 and 0.06 ± 0.13 logMAR, respectively. Similarly, Djodeyre et al15 obtained mean binocular UDVA, CDVA, UIVA (80 cm) and UNVA (40 cm) of 0.01 ± 0.02, 0.00 ± 0.01, 0.20 ± 0.06 and 0.07 ± 0.07 logMAR, respectively, in the case group (<40 years). These values were 0.01 ± 0.02, 0.01 ± 0.01, 0.23 ± 0.06 and 0.08 ± 0.07 logMAR, respectively, for the control group (>50 years). The safety and efficacy indexes were 1.02 and 0.98 for the case group, and 1.03 and 1.00, for the control group, respectively. Our values were in agreement, yielding safety and efficacy indexes of 1.07 and 1.01, respectively. Finally, we would like to point out that Brenner et al16 in their large-sample study reported a mean CDVA of −0.03 ± 0.06 logMAR (range from 0.80 to −0.20), a mean binocular UDVA of −0.03 ± 0.09 logMAR (range from 0.30 to −0.20), and a mean binocular UNVA of 5.08 ± 0.49 (range from 5 to 20, point-type notation), which are more consistent with those reported in our study for the same follow-up period (3 months). Unfortunately, the publications indicated in Table 3 did not report defocus curves; therefore, a direct comparison with our values was not possible. However, the review by Ristvedt et al,10 which analyzed the outcomes in samples of cataract and RLE surgeries with the HP IOL, discussed some studies reporting defocus values. They summarized that the depth-of-focus (the diopter range in which patients show a visual acuity of ≥20/32 [0.2 logMAR]) ranged from 3.00 to 4.00 D under monocular conditions to 4.25 to 5.00 D under binocular conditions (values estimated from the curves published). Our value, illustrated in Figure 4, broadly agrees with these findings (about 5.00D, from +1.00 to −3.75D). Our study in RLE patients also supports the conclusions of these authors, who indicated that bilateral implantation of the FineVision HP IOL is the best approach, providing a continuum of visual acuity at far, intermediate and near distances. Several limitations of our study must be acknowledged. First, despite its prospective design, we only included standard visual performance metrics performed during routine clinical assessment. Future studies should incorporate additional metrics, such as contrast sensitivity under different lighting conditions and reading speed, as well as patient-reported outcome questionnaires to evaluate spectacle independence and photic visual phenomena. Our group carried out a study to assess the clinical outcomes of this IOL model in 116 cataract eyes with different axial lengths21 showing that this lens provides good visual and refractive outcomes for eyes with different axial lengths. So, future studies should consider also this factor in order to confirm that it can be used independently of the axial length of the eye in RLE procedures. An additional limitation is the relatively short follow-up period of 3 months. Taking into account that neuroadaptation in patients implanted with multifocal IOLs improves over time, a longer follow-up would be desirable to confirm our preliminary outcomes. Furthermore, Nd:YAG capsulotomy rates due to posterior capsular opacity were not assessed. Future studies should increase the sample to support the outcomes obtained. In conclusion, this clinical study shows the outcomes of RLE with bilateral implantation of the FineVision HP IOL model in presbyopic patients. The FineVision HP IOL demonstrated favorable short-term refractive accuracy and visual performance in this prospective cohort, although larger comparative studies with longer follow-up are warranted. Disclosure Dr Camille Bosc reports Consulting fees from Hoya surgical, BVI, Zeiss, outside the submitted work. The authors report no other conflicts of interest in this work.